A Novel Nonsteroidal, Topical Anti-inflammatory, Phosphodiesterase 4 Inhibitor, Crisaborole Ointment, Reduced Pruritus and Signs of Atopic Dermatitis in 2 Phase 3 Studies in Children and Adults

Adelaide A Hebert,Wynnis L Tom,Lee T Zane,Mark G Lebwohl,Lawrence F Eichenfield,Matilda H Hughes,Faad Faad,Amy S Paller,Mcr Mcr,Eric L Simpson

doi:10.1542/peds.141.1_meetingabstract.251

A Novel Nonsteroidal, Topical Anti-inflammatory, Phosphodiesterase 4 Inhibitor, Crisaborole Ointment, Reduced Pruritus and Signs of Atopic Dermatitis in 2 Phase 3 Studies in Children and Adults

Adelaide A Hebert, Wynnis L Tom + Show 8 more

https://doi.org/10.1542/peds.141.1_meetingabstract.251

Copy DOI

Publication Date: Jan 1, 2018

Affiliation: The University of Texas Health Science Center at Houston, Rady Children's Hospital-San Diego, Icahn School of Medicine at Mount Sinai, Northwestern University, Oregon Health & Science University

#Crisaborole Topical Ointment #Atopic Dermatitis + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Background: Atopic dermatitis (AD) is an inflammatory skin disease that presents with intense pruritus and red, inflamed lesions. Crisaborole Topical Ointment, 2% (Anacor Pharmaceuticals, Palo Alto, CA), is an investigational, nonsteroidal, topical anti-inflammatory, phosphodiesterase 4 inhibitor for the treatment of AD. Objective: To evaluate the additional predefined efficacy endpoints on the impact of crisaborole ointment on pruritus and signs of AD from 2 Phase …

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.